Regeneron Pharmaceuticals (REGN) Cash from Operations Growth (1y) (2010 - 2026)
Powered by 
Analysis
Regeneron Pharmaceuticals (REGN) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -28.96% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 42.76% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 178.99% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 56.79% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -92.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.96% |
| Mar 31, 2026 | 3.23% |
| Dec 31, 2025 | -7.29% |
| Sep 30, 2025 | 25.36% |
| Jun 30, 2025 | 223.28% |
| Mar 31, 2025 | -30.90% |
| Dec 31, 2024 | 15.89% |
| Sep 30, 2024 | 15.88% |
| Jun 30, 2024 | -65.38% |
| Mar 31, 2024 | 10.60% |
| Dec 31, 2023 | -36.64% |
| Sep 30, 2023 | 77.18% |
| Jun 30, 2023 | 81.15% |
| Mar 31, 2023 | -34.93% |
| Dec 31, 2022 | -27.51% |
| Sep 30, 2022 | -81.58% |
| Jun 30, 2022 | -9.94% |
| Mar 31, 2022 | 214.39% |
| Dec 31, 2021 | 92.73% |
| Sep 30, 2021 | 1,442.35% |